Opinion: ‘Here be dragons’: Long-term survivors like me can help map the boundaries of cancer
“I hope to see you again in six months!” I call back to my radiation…
Category: advocacy
.jpg)
Opinion: A close brush with gun violence made me think about how to confront an epidemic during a pandemic
How do we cope with an epidemic in the middle of a pandemic? It’s a…
STAT+: Hospitals and pharma are both on the hook to help fund infrastructure deal
WASHINGTON — Both hospitals and drug makers are on the hook to help pay for…
Opinion: On menthol cigarettes, social justice theory shouldn’t trump science
This year, 45,000 Black Americans will die from tobacco-related illnesses. The same number will likely…
Opinion: A turning point for children: creating an AIDS-free generation
Forty years after the first AIDS cases were reported, the harsh reality is that deep…
Opinion: Patient advocacy organizations and FDA drug approval: lessons from Aduhelm
In the wake of last month’s controversial Food and Drug Administration approval of Biogen’s Aduhelm,…
Opinion: Circumventing Covid-19 with better ventilation and air quality
Gathering outdoors has provided people a safer alternative to meeting inside during the Covid-19 pandemic….
STAT+: Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill
WASHINGTON — The very next day after Rep. Scott Peters attempted to torpedo House Speaker…
Opinion: Patient advocacy groups and innovators must partner to advance new treatments
People living with debilitating conditions and life-threatening diseases are often put in the terrible position…
STAT+: Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?
WASHINGTON — The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower…
Opinion: Copay assistance should count as part of patients’ cost sharing for medications
The Biden administration has made health equity a priority and it has been a constant…
Operation Warp Speed — now, the ‘CAG’— is here to stay
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Opinion: Public reporting: the first step in addressing the health care industry’s bloated carbon footprint
The health care industry focuses on healing. Yet its pursuit of that mission can cause…
Opinion: India’s doctors — at home and abroad — face Covid’s unrelenting toll
Ravaged by Covid-19, India is desperately trying to contain a pandemic that has infected nearly…
STAT+: Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug
WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want Congress to take a…
The lonely quest to create a commission to investigate Covid-19
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Opinion: FDA should lead the way on new ALS treatments, not Canada and Europe
Following the Food and Drug Administration’s recent decision to give the green light to aducanumab,…
STAT+: Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm
WASHINGTON — Biogen’s expecting to make billions from its newly approved Alzheimer’s drug Aduhelm. But…
STAT+: BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights
WASHINGTON — Everyone wants to know whether Michelle McMurry-Heath, the newly minted president of the…
Opinion: 3D bioprinting can help end organ transplant waitlists — if the FDA stops delaying
Right now, more than 100,000 Americans are waiting for organ transplants. Due to a lack…
STAT+: Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates
WASHINGTON — Sen. Chuck Grassley’s voice boomed through the Senate hearing room — it sounded…
Opinion: If vaccine apartheid exists, vaccine billionaires shouldn’t
To understand why billionaires are a sign of moral and economic failure, look no further…
Opinion: Lessons about marijuana edibles from youth vaping
When it comes to children’s health, parents — and public activism — can make a…
More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows
WASHINGTON — Seventy-two senators and 302 members of the House of Representatives cashed a check…
Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds
WASHINGTON — State lawmakers in Oregon have tried to lower high drug prices from nearly…
Opinion: Scientific publishing’s new weapon for the next crisis: the rapid correction
Some observers have hailed the response to Covid-19 as a triumph for science. A hesitant…
Opinion: With Covid-19, as with HIV, science and partnerships with communities lead the way
Like so many of her generation, Josephine Nabukenya wasn’t aware of her HIV status during…
Opinion: Closing an Indiana county’s syringe services program would be a public health disaster
A 6-year-old program that has reduced overdose deaths while simultaneously preventing new cases of HIV…
Opinion: Created correctly, the Advanced Research Projects Agency for Health will accelerate medical innovation
The U.S. needs a bold initiative to achieve transformative progress in the fight against Alzheimer’s…
Opinion: In ‘vaccine apartheid,’ Nepal is ground zero. It needs U.S. help
The world has reached the era of Covid-19 “vaccine apartheid.” That was the warning this…
Opinion: Restore a better balance to public-private funding of biomedical research
The pharmaceutical industry says that if the U.S. reduces the astronomical drug prices paid by…
Opinion: Beyond a symbolic gesture: What’s needed to turn the IP waiver into Covid-19 vaccines
The Biden administration’s announcement to support an intellectual property (IP) waiver for Covid-19 vaccines was…
Opinion: Luck is not a strategy: The world needs to start preparing now for the next pandemic
As countries grapple with the worst global pandemic in a century, it’s hard to think…
STAT+: Telehealth companies are fueling a lobbying frenzy to protect their Covid boom
WASHINGTON — Telehealth companies, flush with cash after the Covid-19 pandemic spiked both demand and…
STAT+: Key House Democrats’ push for a ‘bipartisan’ drug pricing bill could doom Pelosi’s signature legislation
WASHINGTON — A group of 10 moderate Democrats is urging House Speaker Nancy Pelosi to…
STAT+: How David beat Goliath: Advocacy groups seized a moment, and found allies, in bid to loosen vaccine patent rights
WASHINGTON — They’ve plastered a pharmaceutical CEO’s face on the side of a rented truck…
Opinion: STAT+: Faster approval of complex generics is central to affordable, equitable care
The push to improve Americans’ use of effective and less-expensive generic medications is getting a…
STAT+: Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms
WASHINGTON — Sen. Bob Menendez doesn’t face reelection until 2024, but pharmaceutical executives are already…
Opinion: ALS groups to the FDA and drug sponsors: ‘We won’t be played again’
Working to improve the fight for therapies for amyotrophic lateral sclerosis (ALS, also known as…
Opinion: Needed: an Operation Warp Speed for the opioid epidemic
Despite early challenges in scaling diagnostic testing for Covid-19 and a halting start to the…
Opinion: STAT+: More pharma companies should make the move toward B Corps sustainability
The gradual global shift towards sustainability, with an increased focus on climate change and environmental…
Opinion: End fracking exemptions, a threat to maternal and public health
The adoption of safe, clean, renewable energy is an essential element for sustaining the U.S….
Opinion: To create value, pharma companies should prioritize innovation, not shareholders
Biogen announced its quarterly earnings on April 22 and revealed it had repurchased $600 million…
Opinion: Climate change and human immunity: invest now or pay more later
World leaders, beckoned by President Biden, are assembling on Earth Day, April 22, to create…
Opinion: Needed for long Covid: a less authoritarian approach to understanding, treatment
The public has become increasingly concerned about long Covid — ongoing symptoms and disabilities after…
STAT+: Why hospitals hate Bernie Sanders’ latest health reform push
WASHINGTON — Progressives in Congress, led by Sen. Bernie Sanders, have ramped up pressure on…
Opinion: For-profit nursing homes and hospices are a bad deal for older Americans
Nursing homes and hospice care are supposed to provide safe refuges for older people and…
STAT+: The lobbying juggernaut the American Hospital Association is losing its top advocate at a critical moment for the industry
WASHINGTON — Tom Nickels helped build the American Hospital Association into one of the biggest…
Opinion: It’s time to get health care value assessment right
Trying to gauge the value of new drugs and devices is becoming increasingly important in…
STAT+: PhRMA chief talks strategy — and he’s surprisingly optimistic about drug pricing reform
WASHINGTON — Steve Ubl, who leads the drug industry lobbying powerhouse PhRMA, has a bold…